Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)

Merck Sharp & Dohme (MSD)

Status: Withdrawn

Conditions: Mycoses

Treatments: Drug: Posaconazole or alternative fungal treatment

Study type: Observational

Funder types: Industry

Identifiers

NCT00704951

P05532

Details and patient eligibility

About

The purpose of this program is to determine the frequency of the use of Posaconazole in immunocompromised patients refractory to first line therapy receiving therapeutic treatment based on different pathogens in comparison to other antifungal therapy.

A further objective is to determine the frequency of the use of Posaconazole in immunocompromised patients receiving prophylactic treatment in comparison to other antifungal prophylaxis.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Immunocompromised patients with refractory IFI
• Patients eligible for prophylactic treatment due to anticipated neutropenia for more than 7 days.

Exclusion criteria

• None

Trial design

0 participants in 1 patient group

Patients

Description:

Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections

Treatment:

Drug: Posaconazole or alternative fungal treatment